Needle-free Jet Injection of Reduced-dose, Intradermal, Influenza Vaccine in >= 6 to < 24-month-old Children
Clinical Trial of Safety (Reactogenicity) and Immunogenicity of Needle-free Jet Injection of Reduced-dose, Intradermal Influenza Vaccine (INF) Administered to >= 6 to < 24 Month-old Infants and Toddlers in the Dominican Republic
Sponsor: Bioject Medical Technologies, Inc.
A PHASE1/PHASE2 clinical study on Influenza, this trial is completed. The trial is conducted by Bioject Medical Technologies, Inc. and has accumulated 6 data snapshots since 2006. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Oct 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bioject Medical Technologies, Inc.
- Fundación Dominicana de Infectología, Santo Domingo, Dominican Republic
- Hospital Infantil Dr. Robert Reid Cabral
- MCM Vaccines B.V.
- PATH
- Pan American Health Organization
- Pedro Moro
- World Health Organization
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Santo Domingo, Dominican Republic